RU2005134354A - Антитела против моноцитарного хемоаттрактанта, белка-1, (мср-1) и их применение - Google Patents
Антитела против моноцитарного хемоаттрактанта, белка-1, (мср-1) и их применение Download PDFInfo
- Publication number
- RU2005134354A RU2005134354A RU2005134354/13A RU2005134354A RU2005134354A RU 2005134354 A RU2005134354 A RU 2005134354A RU 2005134354/13 A RU2005134354/13 A RU 2005134354/13A RU 2005134354 A RU2005134354 A RU 2005134354A RU 2005134354 A RU2005134354 A RU 2005134354A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- mcp
- cancer
- animal
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (17)
1. Человеческое моноклональное антитело, которое связывается с МСР-1 и имеет аминокислотную последовательность тяжелой цепи, выбранную из группы, состоящей из SEQ ID NO: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, 90, 94, 98, 102, 106, 110, 114, 118, 122, 126, 130, 134, 138, 142 и 146.
2. Антитело по п.1, которое дополнительно содержит аминокислотную последовательность легкой цепи, выбранную из группы, состоящей из SEQ ID NO: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 144 и 148.
3. Человеческое моноклональное антитело по п.2, где антитело имеет последовательность тяжелой цепи и последовательность легкой цепи, выбранные из одной из 37 комбинаций, определенных в таблице 1.
4. Антитело по п.2, иммобилизованное на нерастворимой матрице.
5. Улучшенный способ определения уровня моноцитарного хемоаттрактанта, белка-1, (МСР-1) в образце, взятом у пациента, где указанный улучшенный способ включает использование анти-МСР-1 антитела по п.2 для детекции уровня МСР-1 в анализе образца, взятого у пациента.
6. Способ по п.5, где указанным образцом, взятым у пациента, является кровь.
7. Композиция, содержащая антитело или его фрагмент по п.2 и фармацевтически приемлемый носитель.
8. Применение антитела в получении лекарственного средства для эффективного лечения опухолевого заболевания у животного, где указанное моноклональное антитело специфически связывается с моноцитарным хемоаттрактантом, белком-1, (МСР-1).
9. Применение по п.8, где указанным антителом является полностью человеческое антитело.
10. Применение по п.8, где указанное опухолевое заболевание выбрано из группы, состоящей из рака молочной железы, рака яичника, рака мочевого пузыря, рака легких, глиобластомы, рака желудка, рака матки, рака почек, рака толстой кишки, рака поджелудочной железы и рака предстательной железы.
11. Применение антитела в получении лекарственного средства для эффективного лечения воспалительного состояния у животного, где указанное моноклональное антитело специфически связывается с моноцитарным хемоаттрактантом, белком-1, (МСР-1).
12. Применение по п.11, где указанным антителом является полностью человеческое антитело.
13. Применение по п.11, где указанное воспалительное состояние выбрано из группы, состоящей из ревматоидного артрита, гломерулонефрита, атеросклероза, псориаза, рестеноза, аутоиммунного заболевания и рассеянного склероза.
14. Способ эффективного лечения животного, страдающего опухолевым заболеванием, включающий выявление животного с опухолевым заболеванием, нуждающегося в лечении; и введение указанному животному терапевтически эффективной дозы полностью человеческого моноклонального антитела, которое специфически связывается с моноцитарным хемоаттрактантом, белком-1, (МСР-1).
15. Способ по п.14, где указанное воспалительное состояние выбрано из группы, состоящей из ревматоидного артрита, гломерулонефрита, атеросклероза, псориаза, рестеноза, аутоиммунного заболевания и рассеянного склероза.
16. Способ эффективного лечения воспалительных состояний, включающий выявление животного с воспалительным состоянием, нуждающегося в лечении; и введение указанному животному терапевтически эффективной дозы полностью человеческого моноклонального антитела, которое специфически связывается с моноцитарным хемоаттрактантом, белком-1, (МСР-1).
17. Способ по п.16, где указанное воспалительное состояние выбрано из группы, состоящей из ревматоидного артрита, гломерулонефрита, атеросклероза, псориаза, рестеноза, аутоиммунного заболевания и рассеянного склероза.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40480202P | 2002-08-19 | 2002-08-19 | |
| US60/404,802 | 2002-08-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005134354A true RU2005134354A (ru) | 2006-06-10 |
| RU2339647C2 RU2339647C2 (ru) | 2008-11-27 |
Family
ID=31888391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005134354/13A RU2339647C2 (ru) | 2002-08-19 | 2003-08-19 | Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7202343B2 (ru) |
| EP (1) | EP1542724A4 (ru) |
| JP (1) | JP4468172B2 (ru) |
| AU (1) | AU2003265575B2 (ru) |
| CA (1) | CA2496419A1 (ru) |
| CO (1) | CO6220978A2 (ru) |
| HR (1) | HRP20050986A2 (ru) |
| IL (1) | IL171674A0 (ru) |
| IS (1) | IS8115A (ru) |
| LT (1) | LT5416B (ru) |
| ME (1) | MEP18108A (ru) |
| NZ (1) | NZ542784A (ru) |
| RS (1) | RS20050834A (ru) |
| RU (1) | RU2339647C2 (ru) |
| UA (1) | UA87979C2 (ru) |
| WO (1) | WO2004016769A2 (ru) |
| ZA (1) | ZA200508994B (ru) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094595B2 (en) * | 2000-10-30 | 2006-08-22 | Sru Biosystems, Inc. | Label-free high-throughput optical technique for detecting biomolecular interactions |
| US7575939B2 (en) | 2000-10-30 | 2009-08-18 | Sru Biosystems, Inc. | Optical detection of label-free biomolecular interactions using microreplicated plastic sensor elements |
| CN104178491B (zh) | 2002-09-06 | 2018-07-03 | 安姆根有限公司 | 治疗性人抗-il-1r1单克隆抗体 |
| US7927822B2 (en) | 2002-09-09 | 2011-04-19 | Sru Biosystems, Inc. | Methods for screening cells and antibodies |
| WO2004080273A2 (en) | 2003-03-12 | 2004-09-23 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating prostate cancer |
| US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
| CA2544924A1 (en) * | 2003-11-05 | 2005-05-19 | Centocor, Inc. | Methods and compositions for treating mcp-1 related pathologies |
| US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
| US8481035B2 (en) * | 2004-04-27 | 2013-07-09 | Northwestern University | Methods for treating chronic pelvic pain syndrome with antibodies that binds MCP-1 or MIP-1A |
| US7794949B2 (en) * | 2004-04-27 | 2010-09-14 | Northwestern University | Biomarkers of chronic pelvic pain syndrome |
| ES2344793T3 (es) | 2004-08-05 | 2010-09-07 | Genentech, Inc. | Antagonistas anti-cmet humanizados. |
| PA8675801A1 (es) * | 2005-05-19 | 2006-12-07 | Centocor Inc | Anticuerpos anti-mcp-1, composiciones, metodos y usos |
| US8114964B2 (en) * | 2005-05-19 | 2012-02-14 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
| US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
| EP1926747A1 (en) * | 2005-08-12 | 2008-06-04 | Schering Corporation | Mcp1 fusions |
| EP1989216A4 (en) * | 2006-03-01 | 2010-03-31 | Univ Michigan | DIAGNOSIS AND TREATMENT OF PROSTATE CANCER |
| WO2007140316A1 (en) * | 2006-05-26 | 2007-12-06 | Board Of Regents, The University Of Texas System | Reverse phase protein array, protein activation and expression signatures, and associated methods |
| US20090297502A1 (en) * | 2006-06-15 | 2009-12-03 | Li Li | Ccr2 antagonists for chronic organ transplantation rejection |
| JP2009544690A (ja) * | 2006-07-24 | 2009-12-17 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | Ｃｃｌ２を含む医薬組成物および炎症の処置のためのその使用 |
| CA2672944A1 (en) | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders |
| EP1958647A1 (en) * | 2007-02-15 | 2008-08-20 | Helmholtz-Zentrum für Infektionsforschung GmbH | Pharmaceutical composition with bacteria for tumor treatment |
| CN101827610A (zh) * | 2007-06-29 | 2010-09-08 | 森托科尔奥索生物科技公司 | 抗mcp-1抗体、组合物、方法和用途 |
| US9778267B2 (en) | 2007-07-11 | 2017-10-03 | X-Body, Inc. | Methods for identifying modulators of ion channels |
| US9134307B2 (en) | 2007-07-11 | 2015-09-15 | X-Body, Inc. | Method for determining ion channel modulating properties of a test reagent |
| AU2008287037B2 (en) * | 2007-08-10 | 2013-10-10 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| JP5641599B2 (ja) * | 2007-08-24 | 2014-12-17 | 学校法人慶應義塾 | 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤 |
| US9855370B2 (en) * | 2008-01-08 | 2018-01-02 | Yale University | Compositions and methods for promoting patency of vascular grafts |
| US8257936B2 (en) | 2008-04-09 | 2012-09-04 | X-Body Inc. | High resolution label free analysis of cellular properties |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CN102076355B (zh) * | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| TW201008580A (en) * | 2008-06-03 | 2010-03-01 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| US9109026B2 (en) * | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
| JP5674654B2 (ja) * | 2008-07-08 | 2015-02-25 | アッヴィ・インコーポレイテッド | プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用 |
| CN102239180B (zh) | 2008-08-18 | 2014-12-31 | 辉瑞大药厂 | 抗ccr2抗体 |
| NZ591187A (en) * | 2008-08-20 | 2012-07-27 | Probiodrug Ag | Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe) |
| US8262879B2 (en) | 2008-09-03 | 2012-09-11 | Nabsys, Inc. | Devices and methods for determining the length of biopolymers and distances between probes bound thereto |
| MX2011003855A (es) * | 2008-10-22 | 2011-12-16 | Inst Research In Biomedicine | Metodos para producir anticuerpos a partir de celulas plasmaticas. |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| RU2393216C1 (ru) * | 2009-02-06 | 2010-06-27 | Александр Валентинович Шишкин | Способ комбинированного иммунологического исследования клеток с помощью биочипа |
| MX2011009897A (es) | 2009-03-20 | 2011-12-08 | Amgen Inc | Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7. |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| AU2010286516B2 (en) | 2009-08-28 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Antikine antibodies that bind to multiple CC chemokines |
| NZ598929A (en) * | 2009-09-01 | 2014-05-30 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
| BR112012008833A2 (pt) * | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CN102947705A (zh) * | 2010-02-18 | 2013-02-27 | 前体生物药物股份公司 | 通过确定焦谷氨酸修饰的mcp-1诊断炎性疾病的方法和谷氨酰胺酰基环化酶抑制剂的筛选方法 |
| US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
| PE20131412A1 (es) | 2010-08-03 | 2014-01-19 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2608803A4 (en) | 2010-08-26 | 2014-01-15 | Abbvie Inc | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| AU2012239997A1 (en) * | 2011-04-07 | 2013-10-17 | Amgen Inc. | Novel EGFR binding proteins |
| KR20140045440A (ko) | 2011-06-30 | 2014-04-16 | 제넨테크, 인크. | 항-c-met 항체 제제 |
| UY34558A (es) | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
| UY34813A (es) | 2012-05-18 | 2013-11-29 | Amgen Inc | Proteínas de unión a antígeno dirigidas contra el receptor st2 |
| RU2501017C1 (ru) * | 2012-10-18 | 2013-12-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский институт акушерства и педиатрии" Министерства здравоохранения и социального развития Российской Федерации | Способ прогнозирования невынашивания беременности в ранние сроки |
| KR20190096459A (ko) | 2012-11-01 | 2019-08-19 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| BR112015023797A2 (pt) | 2013-03-15 | 2017-10-24 | Abbvie Inc | proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17 |
| HK1219891A1 (zh) * | 2013-08-06 | 2017-04-21 | 国立大学法人九州大学 | 有机酸聚合物作为有效组分的、预防或抑制癌细胞生存的药物 |
| EP3041863A4 (en) | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| WO2015148531A1 (en) | 2014-03-24 | 2015-10-01 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| JP6957468B2 (ja) | 2015-12-11 | 2021-11-02 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 最適化された患者特異的組織操作血管移植片のためのシステムおよび方法 |
| CA3029074A1 (en) | 2016-06-22 | 2018-01-25 | William Warren HARLESS | Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| KR20190118172A (ko) | 2017-02-08 | 2019-10-17 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
| EP3579866A4 (en) * | 2017-02-08 | 2020-12-09 | Dragonfly Therapeutics, Inc. | VARIABLE DOMAINS OF ANTIBODY HEAVY CHAINS TARGETING THE NKG2D RECEIVER |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| US12503700B2 (en) | 2017-03-14 | 2025-12-23 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| CN108048408B (zh) * | 2018-01-26 | 2020-02-07 | 扬州大学 | 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用 |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| CN112040971A (zh) | 2018-02-08 | 2020-12-04 | 蜻蜓疗法股份有限公司 | 涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法 |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| US12325737B2 (en) | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| AU2019318083A1 (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| AR118898A1 (es) * | 2019-05-09 | 2021-11-10 | Merus Nv | Dominios variantes para multimerizar proteínas y su separación |
| CN114450593A (zh) | 2019-09-26 | 2022-05-06 | 美国安进公司 | 产生抗体组合物的方法 |
| EP4309722A3 (en) | 2019-12-13 | 2024-08-07 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| JP2023548767A (ja) | 2020-10-15 | 2023-11-21 | アムジエン・インコーポレーテツド | 抗体製造方法における相対不対グリカン |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| EP4352094A1 (en) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| US20250076309A1 (en) | 2021-10-05 | 2025-03-06 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| WO2023122211A2 (en) * | 2021-12-21 | 2023-06-29 | Duke University | Coronavirus antibodies and uses thereof |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2023213400A1 (en) * | 2022-05-05 | 2023-11-09 | Institute For Research In Biomedicine | Antibodies against chemokines, method for identifying said antibodies and uses thereof |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| JPH0967399A (ja) * | 1995-08-30 | 1997-03-11 | Mitsui Toatsu Chem Inc | 抗ｍｃｐ−１ヒトモノクローナル抗体 |
| AU711626B2 (en) * | 1995-09-27 | 1999-10-21 | Shionogi & Co., Ltd. | Type CC chemokine-like protein |
| JPH1160502A (ja) * | 1997-08-12 | 1999-03-02 | Teijin Ltd | 脳梗塞症治療薬もしくは予防薬 |
| AU6174301A (en) * | 2000-05-19 | 2001-12-03 | Us Health | Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity |
| GB0016138D0 (en) * | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
-
2003
- 2003-08-19 NZ NZ542784A patent/NZ542784A/en active Application Filing
- 2003-08-19 CA CA002496419A patent/CA2496419A1/en not_active Abandoned
- 2003-08-19 RS YUP-2005/0834A patent/RS20050834A/sr unknown
- 2003-08-19 WO PCT/US2003/026232 patent/WO2004016769A2/en not_active Ceased
- 2003-08-19 EP EP03788686A patent/EP1542724A4/en not_active Withdrawn
- 2003-08-19 UA UAA200510566A patent/UA87979C2/ru unknown
- 2003-08-19 JP JP2004529174A patent/JP4468172B2/ja not_active Expired - Lifetime
- 2003-08-19 HR HR20050986A patent/HRP20050986A2/xx not_active Application Discontinuation
- 2003-08-19 US US10/644,277 patent/US7202343B2/en not_active Expired - Fee Related
- 2003-08-19 AU AU2003265575A patent/AU2003265575B2/en not_active Ceased
- 2003-08-19 ME MEP-181/08A patent/MEP18108A/xx unknown
- 2003-08-19 RU RU2005134354/13A patent/RU2339647C2/ru not_active IP Right Cessation
-
2005
- 2005-10-30 IL IL171674A patent/IL171674A0/en unknown
- 2005-11-01 IS IS8115A patent/IS8115A/is unknown
- 2005-11-07 ZA ZA200508994A patent/ZA200508994B/xx unknown
- 2005-11-08 CO CO05113477A patent/CO6220978A2/es not_active Application Discontinuation
- 2005-11-08 LT LT2005099A patent/LT5416B/lt not_active IP Right Cessation
-
2006
- 2006-12-19 US US11/641,128 patent/US7482434B2/en not_active Expired - Fee Related
- 2006-12-19 US US11/641,633 patent/US7687606B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1542724A4 (en) | 2005-10-19 |
| US20050058639A1 (en) | 2005-03-17 |
| US7482434B2 (en) | 2009-01-27 |
| CA2496419A1 (en) | 2004-02-26 |
| MEP18108A (en) | 2010-06-10 |
| IS8115A (is) | 2005-11-01 |
| EP1542724A2 (en) | 2005-06-22 |
| WO2004016769A2 (en) | 2004-02-26 |
| RU2339647C2 (ru) | 2008-11-27 |
| US7202343B2 (en) | 2007-04-10 |
| LT5416B (lt) | 2007-04-25 |
| JP2005536534A (ja) | 2005-12-02 |
| CO6220978A2 (es) | 2010-11-19 |
| US7687606B2 (en) | 2010-03-30 |
| ZA200508994B (en) | 2006-09-27 |
| WO2004016769A3 (en) | 2004-10-14 |
| AU2003265575A1 (en) | 2004-03-03 |
| RS20050834A (sr) | 2007-12-31 |
| NZ542784A (en) | 2008-07-31 |
| HRP20050986A2 (en) | 2006-11-30 |
| LT2005099A (en) | 2006-11-27 |
| US20070116708A1 (en) | 2007-05-24 |
| US20070128112A1 (en) | 2007-06-07 |
| IL171674A0 (en) | 2009-02-11 |
| UA87979C2 (ru) | 2009-09-10 |
| AU2003265575B2 (en) | 2009-12-10 |
| JP4468172B2 (ja) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005134354A (ru) | Антитела против моноцитарного хемоаттрактанта, белка-1, (мср-1) и их применение | |
| Yoshimura | The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments | |
| Hardell et al. | Further aspects on cellular and cordless telephones and brain tumours | |
| NZ513498A (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
| Ciechanowska et al. | Changes in macrophage inflammatory protein-1 (MIP-1) family members expression induced by traumatic brain injury in mice | |
| ATE403001T1 (de) | Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs | |
| JP5586368B2 (ja) | 腫瘍マーカーとしてのｎ１，ｎ１２−ジアセチルスペルミン | |
| PT1231268E (pt) | Bancos de anticorpos policlonais | |
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| PE20021151A1 (es) | Uso de anticuerpos anti-tnf como farmacos en el tratamiento de trastornos septicos de racientes anemicos | |
| ATE541860T1 (de) | Humane antikörper gegen cd40 zur therapie von b- zell tumoren | |
| RU2008126932A (ru) | Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами | |
| CY1111011T1 (el) | Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος | |
| UA90082C2 (ru) | Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25 | |
| EP0966300A4 (en) | TREATMENT OF AUTOIMMUNE DISEASES, INCLUDING AIDS | |
| RU2008128244A (ru) | Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2 | |
| DE50306067D1 (de) | Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern | |
| RU2011103199A (ru) | Антитела против cdh3, меченные радиоизотопной меткой, и их применение | |
| DE69717664D1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
| RU2015105168A (ru) | Метод диагностики рака | |
| EA200601264A1 (ru) | Соединения для адресной доставки препарата к ткани или органу-мишени | |
| RU2015105255A (ru) | Метод диагностики рака | |
| RU2012120706A (ru) | Диагностические и терапевтические способы | |
| Ping et al. | The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells | |
| EP2984108A1 (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100820 |